Recombinant Human B7-H7/HHLA2 His-tag Protein, CF

When Recombinant Human TMIGD2/CD28H (8316-TR) is immobilized at 2.5 μg/mL (100 μL/well), Recombinant Human B7 H7/HHLA2 His-tag (Catalog # 10475-B7) that produces a 50% optimal binding response is found to be 0.8-4.8 μg/mL.

2 μg/lane of Recombinant Human B7-H7/HHLA2 His-tag Protein (Catalog # 10475-B7) was resolved withSDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized bysilver stain, showing bands at kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human B7-H7/HHLA2 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human TMIGD2/CD28H (Catalog # 8316-TR) is immobilized at 2.5 µg/mL (100 µL/ well), Recombinant Human B7‑H7/HHLA2 His-tag (Catalog # 10475-B7) that produces a 50% optimal binding response is found to be 0.8-4.8 µg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human B7-H7/HHLA2 protein
  Phe29-Asn344, with a C-terminal 6-His tag
• Accession #: NP_009003.1
• N-terminal Sequence: Phe29 & Ile30
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 37 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 57-64 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human B7-H7/HHLA2 His-tag Protein, CF

• B7H7
• B7-H7
• HERV-H LTR-associating 2
• HERV-H LTR-associating protein 2
• HHLA2
• Human endogenous retrovirus-H long terminal repeat-associating protein 2

Background

B7-H7, also known as HHLA2 (HERV-H LTR-associating 2), is a member of the B7 family of immune regulatory proteins (1, 2). Mature human B7-H7 consists of a 322 amino acid (aa) extracellular domain (ECD) with three immunoglobulin-like domains, a 21 aa transmembrane segment, and a 49 aa cytoplasmic domain (3-5). B7‑H7 is constitutively expressed on monocytes and is up-regulated by LPS and IFN-gamma stimulation. It is expressed on LPS/IFN-gamma treated B cells but not on resting B cells (5). B7-H7 binds to cell surface determinants on resting and mature T cells, B cells, and monocytes as well as on immature and mature dendritic cells (5). Soluble B7-H7 inhibits the proliferation of activated CD4⁺ and CD8⁺ T cells and their production of IFN-gamma , TNF-alpha , IL-5, IL-10, IL-13, IL-17A, and IL-22 (5).

1. Zou, W. and L. Chen (2008) Nat. Rev. Immunol. 8:467.
2. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
3. Mager, D.L. et al. (1999) Genomics 59:255.
4. Flajnik, M.M. et al. (2012) Immunogenetics 64:571.
5. Zhao, R. et al. (2013) Proc. Natl. Acad. Sci. USA 110:9879.

Bioinformatics

• Uniprot:
  • NP_009003.1()